JP2001506978A - 置換1―[2[ビス(アリール)メトキシ]エチル]―ピペラジンおよび―ホモピペラジンのヒドロキシル化類似物の持続性放出誘導体およびそのドパミン再アップテイクの非競合的拮抗物質としての使用 - Google Patents
置換1―[2[ビス(アリール)メトキシ]エチル]―ピペラジンおよび―ホモピペラジンのヒドロキシル化類似物の持続性放出誘導体およびそのドパミン再アップテイクの非競合的拮抗物質としての使用Info
- Publication number
- JP2001506978A JP2001506978A JP52077598A JP52077598A JP2001506978A JP 2001506978 A JP2001506978 A JP 2001506978A JP 52077598 A JP52077598 A JP 52077598A JP 52077598 A JP52077598 A JP 52077598A JP 2001506978 A JP2001506978 A JP 2001506978A
- Authority
- JP
- Japan
- Prior art keywords
- derivative
- individual
- bis
- methoxy
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.1−[2−[ビス−(4−フルオロフェニル)メトキシ]エチル]−4−[ 3−フェニルプロピル]ピペラジンのヒドロキシル化類似物のアルカン酸エステ ル誘導体であって、該アルカン酸エステルがC6-20アルカン酸エステルおよびC6-20 シクロアルキルアルカン酸エステルからなる群より選ばれるアルカン酸エス テル誘導体。 2.前記誘導体が、(+/−)1−[2−[ビス−(4−フルオロフェニル)メ トキシ]エチル]−4−[3−フェニル−3−ヒドロキシ−プロピル]ピペラジ ンである請求項1記載の誘導体。 3.請求項1記載の誘導体および医薬的に許容される担体を含む医薬組成物。 4.前記誘導体が、少なくとも約30日の薬理学的半減期を有する請求項3記載 の医薬組成物。 5.前記誘導体が、(+/−)1−[2−[ビス−(4−フルオロフェニル)メ トキシ]エチル]−4−[3−フェニル−3−ヒドロキシ−プロピル]ピペラジ ンである請求項3記載の医薬組成物。 6.臀部および大腿部からなる群より選ばれる部位での蓄積注射に適切である請 求項3記載の医薬組成物。 7.臀部および大腿部からなる群より選ばれる部位での蓄積注射に適切である請 求項4記載の医薬組成物。 8.臀部および大腿部からなる群より選ばれる部位での蓄積注射に適切である請 求項5記載の医薬組成物。 9.ドパミン輸送体に結合する化合物をそれを必要とする個体に提供する方法で あって、該方法は該個体に請求項1記載の誘導体を所望の効果を達成するのに十 分な量で投与することを含む方法。 10.ドパミン再アップテイク阻害剤またはドパミン放出体あるいはノルエピネ フリンおよび/またはセロトニン再アップテイク阻害剤の拮抗物質をそれを必要 とする個体に提供する方法であって、該方法は該個体に請求項1記載の誘導体を 、 該個体における該誘導体の持続性放出の間、該個体において該阻害剤または放出 体に拮抗するのに十分な量で投与することを含む方法。 11.前記誘導体が、(+/−)1−[2−[ビス−(4−フルオロフェニル) メトキシ]エチル]−4−[3−フェニル−3−ヒドロキシ−プロピル]ピペラ ジンである請求項9記載の方法。 12.前記誘導体が、蓄積注射により投与される請求項9記載の方法。 13.前記誘導体が、蓄積注射により投与される請求項10記載の方法。 14.前記蓄積注射が、臀部および大腿部からなる群より選ばれる部位に注射さ れる請求項11記載の方法。 15.前記蓄積注射が、臀部および大腿部からなる群より選ばれる部位に注射さ れる請求項12記載の方法。 16.前記持続性放出が、少なくとも約30日の期間継続する請求項9記載の方 法。 17.前記持続性放出が、少なくとも約30日の期間継続する請求項10記載の 方法。 18.前記個体がコカインを乱用している個体である請求項9記載の方法。 19.前記個体がコカインを乱用している個体である請求項10記載の方法。 20.コカインを乱用している個体に請求項1記載の化合物を投与する方法であ って、該個体に、臀部および大腿部からなる群より選ばれる部位での蓄積注射に より、少なくとも約30日の期間の間、このような個体における該誘導体の持続 性放出の間、該個体において該コカインに拮抗するのに十分な量で請求項1記載 の誘導体を含む、蓄積注射が可能な医薬組成物を投与することを含む方法。 21.前記誘導体が、(+/−)1−[2−[ビス−(4−フルオロフェニル) メトキシ]エチル]−4−[3−フェニル−3−ヒドロキシ−プロピル]ピペラ ジンである請求項19に記載の方法。 22.メタンフェタミンまたはアンフェタミンを乱用している個体に請求項1記 載の化合物を投与する方法であって、該個体に、臀部および大腿部からなる群よ り選ばれる部位での蓄積注射により、少なくとも約30日の期間の間、このよう な個体における該誘導体の持続性放出の間、該個体において該メタンフェタミン またはアンフェタミンに拮抗するのに十分な量で請求項1記載の誘導体を含む、 蓄積注射が可能な医薬組成物を投与することを含む方法。 23.前記誘導体が、(+/−)1−[2−[ビス−(4−フルオロフェニル) メトキシ]エチル]−4−[3−フェニル−3−ヒドロキシ−プロピル]ピペラ ジンである請求項21に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3024896P | 1996-10-31 | 1996-10-31 | |
US60/030,248 | 1996-10-31 | ||
PCT/US1997/019758 WO1998018769A1 (en) | 1996-10-31 | 1997-10-31 | Sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use as noncompetitive antagonists of dopamine reuptake |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001506978A true JP2001506978A (ja) | 2001-05-29 |
JP2001506978A5 JP2001506978A5 (ja) | 2005-02-10 |
Family
ID=21853277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52077598A Ceased JP2001506978A (ja) | 1996-10-31 | 1997-10-31 | 置換1―[2[ビス(アリール)メトキシ]エチル]―ピペラジンおよび―ホモピペラジンのヒドロキシル化類似物の持続性放出誘導体およびそのドパミン再アップテイクの非競合的拮抗物質としての使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US6387389B1 (ja) |
EP (1) | EP0937053A1 (ja) |
JP (1) | JP2001506978A (ja) |
AU (1) | AU5157798A (ja) |
CA (1) | CA2269328A1 (ja) |
WO (1) | WO1998018769A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523735A (ja) * | 2006-01-12 | 2009-06-25 | ウェイン ステイト ユニバーシティー | 三置換体の2−ベンズヒドリル−5−ベンジルアミノ−テトラヒドロピラン−4−オール、および、6−ベンズヒドリル−4−ベンジルアミノ−テトラヒドロピラン−3−オール類似体、ならびに、新規な3,6−二置換体のピラン誘導体 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002332659A1 (en) * | 2001-08-21 | 2003-03-03 | Sepracor, Inc. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
CN1181065C (zh) * | 2002-05-08 | 2004-12-22 | 上海医药工业研究院 | 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用 |
WO2004063150A2 (en) * | 2003-01-06 | 2004-07-29 | The General Hospital Corporation | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process |
US7381822B2 (en) * | 2004-03-31 | 2008-06-03 | The General Hospital Corporation | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process |
EP1734948B1 (en) | 2004-04-16 | 2014-06-11 | Wayne State University | Tri-substitued 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives |
US20120028992A1 (en) * | 2010-08-02 | 2012-02-02 | Brown Arthur M | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals |
WO2014059338A1 (en) * | 2012-10-11 | 2014-04-17 | Chanrx Corporation | Novel piperazine compounds, pharmaceutical compositions containing the same and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals |
WO2014059367A1 (en) * | 2012-10-11 | 2014-04-17 | Chanrx Corporation | Pharmaceutical compositions containing enantiomerically pure and/or racemic mixtures of chiral piperazine compounds and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals through administration of said compositions |
WO2014059346A1 (en) * | 2012-10-11 | 2014-04-17 | Brown Arthur M | Methods for the treatment of conditions involving dopamine through administration of piperazine compounds |
EP2964611B1 (en) | 2013-03-08 | 2022-10-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof |
WO2014176497A1 (en) * | 2013-04-26 | 2014-10-30 | Chanrx Corporation | Novel metabolites of vanoxerine compounds, pharmaceutical compositions containing the same and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals |
WO2015073967A1 (en) * | 2013-11-15 | 2015-05-21 | Brown Arthur M | Novel metabolites of vanoxerine compounds for the treatment of dopaminergic diseases |
WO2015119938A1 (en) * | 2014-02-05 | 2015-08-13 | Chanrx Corporation | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia, and/or maintaining normal sinus rhythm in mammals |
WO2019094856A1 (en) | 2017-11-13 | 2019-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Atypical inhibitors of monoamine transporters; method of making; and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3408356A (en) * | 1965-08-31 | 1968-10-29 | Squibb & Sons Inc | Long chain esters of 4'-fluoro-4-[4-hydroxy-4-(alpha, alpha, alpha-trifluorotolyl)piperi-dino]butyrophenone and the like |
FR2350100A1 (fr) * | 1976-05-06 | 1977-12-02 | Sauba Lab | Derives disubstitues de la piperazine, leur procede de preparation et leurs applications therapeutiques |
JPS568318A (en) * | 1979-06-28 | 1981-01-28 | Janssen Pharmaceutica Nv | Non oral long acting composition of haloperidol and bromperidol derivative |
NL8202636A (nl) | 1982-06-29 | 1984-01-16 | Gist Brocades Nv | Piperazinederivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten die deze verbindingen bevatten. |
CA2064574A1 (en) | 1989-08-03 | 1991-02-04 | Richard B. Rothman | Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists |
DK178490D0 (da) | 1990-07-26 | 1990-07-26 | Novo Nordisk As | 1,4-disubstituerede piperaziner |
-
1997
- 1997-10-31 EP EP97946401A patent/EP0937053A1/en not_active Withdrawn
- 1997-10-31 AU AU51577/98A patent/AU5157798A/en not_active Abandoned
- 1997-10-31 JP JP52077598A patent/JP2001506978A/ja not_active Ceased
- 1997-10-31 CA CA002269328A patent/CA2269328A1/en not_active Abandoned
- 1997-10-31 WO PCT/US1997/019758 patent/WO1998018769A1/en not_active Application Discontinuation
- 1997-10-31 US US09/269,926 patent/US6387389B1/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523735A (ja) * | 2006-01-12 | 2009-06-25 | ウェイン ステイト ユニバーシティー | 三置換体の2−ベンズヒドリル−5−ベンジルアミノ−テトラヒドロピラン−4−オール、および、6−ベンズヒドリル−4−ベンジルアミノ−テトラヒドロピラン−3−オール類似体、ならびに、新規な3,6−二置換体のピラン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
EP0937053A1 (en) | 1999-08-25 |
US6387389B1 (en) | 2002-05-14 |
AU5157798A (en) | 1998-05-22 |
WO1998018769A1 (en) | 1998-05-07 |
CA2269328A1 (en) | 1998-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10653662B2 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
EP1617832B1 (en) | Compositions for affecting weight loss | |
JP3221611B2 (ja) | 物質乱用障害の治療用医薬組成物 | |
AU2006268098B2 (en) | Use of 3,1IB-CIS-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease | |
US9801847B2 (en) | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders | |
JP2001506978A (ja) | 置換1―[2[ビス(アリール)メトキシ]エチル]―ピペラジンおよび―ホモピペラジンのヒドロキシル化類似物の持続性放出誘導体およびそのドパミン再アップテイクの非競合的拮抗物質としての使用 | |
US10143676B2 (en) | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders | |
JPH08504189A (ja) | 低/非たんでき性オピオイド鎮痛剤の確認及び使用方法 | |
US20090042972A1 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
TW200418446A (en) | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | |
EP0971713A1 (en) | Use of cholinesterase inhibitors to treat disorders of attention | |
US20090042971A1 (en) | Method of using low-dose doxepin for the improvement of sleep | |
AU1915192A (en) | Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins | |
CN110831584B (zh) | 具有新颖的组合物、组合的靶向药物拯救及其方法 | |
EP2412705A1 (en) | Novel therapeutic agent for cognitive impairment | |
US6221858B1 (en) | Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders | |
JP2000505057A (ja) | 膜発現の阻害を目的とするギンゴリド | |
MXPA00007127A (en) | Pharmaceutically active morpholinol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040527 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071225 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080324 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080513 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20080930 |